Gina Snyder
Medical · Shelby, NCNPI 1366817066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 583 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$967
- Otsuka America Pharmaceutical, Inc.$847
- plus $4K from 26 others
What the payments were for
- Food & beverage$10,36797%
- Education$3143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 63 | $1,421 |
| Neurocrine Biosciences, Inc. | 78 | $1,379 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,148 |
| AbbVie | 107 | $1,127 |
| Vanda Pharmaceuticals Inc. | 43 | $967 |
| Otsuka America Pharmaceutical, Inc. | 42 | $847 |
| Alkermes, Inc. | 18 | $516 |
| Axsome Therapeutics, Inc. | 14 | $512 |
| Lundbeck LLC | 22 | $382 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $339 |
| Supernus Pharmaceuticals, Inc. | 9 | $303 |
| Johnson & Johnson | 16 | $258 |
| Lilly USA, LLC | 12 | $236 |
| Corium, LLC | 11 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $141 |
| E.r. Squibb & Sons, L.L.C. | 6 | $127 |
| Merck | 8 | $119 |
| Novo Nordisk | 7 | $110 |
| Eisai Inc. | 5 | $97 |
| Bayer | 5 | $86 |
| Sunovion Pharmaceuticals Inc. | 8 | $66 |
| GSK | 2 | $44 |
| Noven Therapeutics, LLC | 3 | $41 |
| Amgen | 3 | $38 |
| AstraZeneca | 2 | $36 |
| Antares Pharma, Inc. | 2 | $34 |
| Inari Medical, Inc. | 1 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Almatica Pharma LLC | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Abbott | 1 | $26 |
| Clarus Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,681 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 17 | $205,740 |
| IngrezzaValbenazine Tosylate | 21 | $172,504 |
| Invega SustennaPaliperidone Palmitate | 46 | $164,455 |
| VraylarCariprazine Hcl | 120 | $157,601 |
| AustedoDeutetrabenazine | 17 | $108,191 |
| UzedyRisperidone | 18 | $67,441 |
| RexultiBrexpiprazole | 31 | $44,532 |
| FanaptIloperidone | 14 | $37,249 |
| Abilify MaintenaAripiprazole | 12 | $30,809 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $26,290 |
| TrintellixVortioxetine Hydrobromide | 48 | $25,960 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $19,509 |
| Lurasidone Hcl | 61 | $18,897 |
| Paliperidone ErPaliperidone | 54 | $9,473 |
| Clozapine | 104 | $7,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $1,421 | $381,37352 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,379 | $172,50421 claims |
| Johnson & JohnsonInvega Sustenna | $258 | $164,45546 claims |
| AbbVieVraylar | $1,127 | $157,601120 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $847 | $75,34043 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $967 | $37,24914 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $339 | $31,90165 claims |
| Alkermes, Inc.Lybalvi | $516 | $26,29015 claims |
| Axsome Therapeutics, Inc.Auvelity | $512 | $19,50919 claims |
| Lilly USA, LLCOlanzapine | $236 | $5,309203 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.
Other medical in Shelby
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$265K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- David TaylorMorehead City$40K
- Katherine CardSalisbury$39K
- John RobbinsWinston Salem$26K
- Ashley TipperStatesville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.